A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Who is this study for? Adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement
What treatments are being studied? Repotrectinib
Status: Recruiting
Location: See all (175) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Healthy Volunteers: No
View:

• Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.

• ECOG PS 0-1.

• Age ≥18 (or age ≥ 20 of age as required by local regulation).

• Capability to swallow capsules intact (without chewing, crushing, or opening).

• At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.

• Prior cytotoxic chemotherapy is allowed.

• Prior immunotherapy is allowed.

• Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

• Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.

• Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation

• Life expectancy ≥ 3 months.

• PHASE 2 Key Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.

• Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:

• a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.

• • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.

• OR

• a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.

• Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

• Age ≥12 (or age ≥ 20 as required by local regulation).

• Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.

• At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.

• Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.

• i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors

• Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.

• Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation

• Life expectancy ≥ 3 months.

Locations
United States
Arizona
Yuma Regional Medical Center PHASE 2
Enrolling by invitation
Yuma
California
City of Hope PHASE 2
Recruiting
Duarte
Adventist Health Glendale PHASE 2
Recruiting
Glendale
MemorialCare Long Beach PHASE 2
Enrolling by invitation
Long Beach
Pacific Shores Oncology PHASE 2
Recruiting
Long Beach
UC Irvine Health, Chao Family Comprehensive Cancer Center PHASE 1 (recruiting) & PHASE 2 (recruiting)
Recruiting
Orange
Ventura County Hematology Oncology Specialists PHASE 2
Enrolling by invitation
Oxnard
UC San Diego Moores Cancer Center PHASE 2
Recruiting
San Diego
St Joseph's Heritage Healthcare PHASE 2
Recruiting
Santa Rosa
Colorado
University of Colorado Denver PHASE 1 (recruiting) & PHASE 2 (recruiting)
Recruiting
Aurora
Washington, D.c.
Georgetown Lombardi Comprehensive Cancer Center PHASE 2
Recruiting
Washington
Johns Hopkins Kimmel Cancer Center PHASE 2
Recruiting
Washington
Florida
Memorial Healthcare System PHASE 2
Recruiting
Hollywood
Cancer Specialists of North Florida PHASE 2
Enrolling by invitation
Jacksonville
Ocala Oncology PHASE 2
Enrolling by invitation
Ocala
Moffitt Cancer Center PHASE 2
Recruiting
Tampa
Georgia
University Cancer and Blood Center PHASE 2
Recruiting
Athens
Columbus Regional Research Institute PHASE 2
Recruiting
Columbus
Hawaii
Hawaii Cancer Care PHASE 2
Enrolling by invitation
Honolulu
Illinois
University of Chicago PHASE 2
Recruiting
Chicago
Illinois Cancer Care PHASE 2
Recruiting
Peoria
Indiana
Fort Wayne Medical Oncology and Hematology PHASE 2
Enrolling by invitation
Fort Wayne
Beacon Health PHASE 2
Enrolling by invitation
South Bend
Louisiana
Pontchartrain Cancer Center (QCCA) PHASE 2
Enrolling by invitation
Covington
Massachusetts
Massachusetts General Hospital PHASE 1 (recruiting) & PHASE 2 (recruiting)
Recruiting
Boston
MGH Satellite - Dana-Farber Cancer Institute PHASE 2
Recruiting
Boston
Southcoast PHASE 2
Enrolling by invitation
Fairhaven
Maryland
University of Maryland School of Medicine PHASE 2
Recruiting
Baltimore
The Center for Cancer & Blood Disorders - Maryland PHASE 2
Enrolling by invitation
Bethesda
Frederick Health - James M Stockman Cancer Institute PHASE 2
Enrolling by invitation
Frederick
Michigan
University of Michigan Rogel Cancer Center PHASE 2
Withdrawn
Ann Arbor
Henry Ford Health System PHASE 2
Recruiting
Detroit
Karmanos Cancer Institute PHASE 2
Recruiting
Detroit
Sparrow Health System PHASE 2
Enrolling by invitation
Lansing
Minnesota
Regions Hospital Cancer Care Center PHASE 2
Recruiting
Saint Paul
Missouri
Central Care Cancer Center PHASE 2
Recruiting
Bolivar
Mosaic Life Care PHASE 2
Enrolling by invitation
Saint Joseph
Washington University Siteman Cancer Center PHASE 2
Recruiting
Saint Louis
North Carolina
Southeastern Medical Oncology Center PHASE 2
Recruiting
Goldsboro
New Jersey
New Jersey Cancer Care and Blood Disorders PHASE 2
Enrolling by invitation
Belleville
Summit Medical Group PHASE 2
Enrolling by invitation
Berkeley Heights
Rutgers Cancer Institute PHASE 2
Recruiting
New Brunswick
New York
Memorial Sloan Kettering Cancer Center PHASE 1 (recruiting) & PHASE 2 (Recruiting)
Recruiting
New York
NYU Langone Health PHASE 2
Recruiting
New York
Ohio
Gabrail Cancer Center PHASE 2
Recruiting
Canton
TriHealth Cancer Institute PHASE 2
Recruiting
Cincinnati
Cleveland Clinic PHASE 2
Terminated
Cleveland
Ohio State Wexner Medical Center PHASE 2
Recruiting
Columbus
OhioHealth PHASE 2
Enrolling by invitation
Columbus
University of Toledo PHASE 2
Withdrawn
Toledo
Oklahoma
Oklahoma Cancer Specialists and Research Institute Tulsa, OK (OCSRI) (QCCA) PHASE 2
Enrolling by invitation
Tulsa
Pennsylvania
Gettysburg PHASE 2
Enrolling by invitation
Gettysburg
Fox Chase Cancer Center PHASE 2
Recruiting
Philadelphia
South Dakota
Avera Cancer Institute Center for Precision Oncology PHASE 2
Enrolling by invitation
Sioux Falls
Sanford Health PHASE 2
Enrolling by invitation
Sioux Falls
Tennessee
Baptist Memorial Hospital Baptist Cancer Center PHASE 2
Recruiting
Memphis
Texas
UT Southwestern Medical Center PHASE 2
Recruiting
Dallas
MD Anderson Cancer Center - The University of Texas PHASE 2
Recruiting
Houston
Oncology Consultants P.A. PHASE 2
Withdrawn
Houston
Lumi Research PHASE 2
Recruiting
Kingwood
Utah
Utah Cancer Specialists PHASE 2
Enrolling by invitation
Salt Lake City
Virginia
Virginia Cancer Specialists PHASE 2
Recruiting
Fairfax
Hematology Oncology Associates of Fredericksburg PHASE 2
Enrolling by invitation
Fredericksburg
Washington
PeaceHealth - Bellingham (NW) PHASE 2
Enrolling by invitation
Bellingham
UW Seattle Cancer Care Alliance PHASE 2
Recruiting
Seattle
Wisconsin
ThedaCare PHASE 2
Recruiting
Appleton
Other Locations
Australia
Flinders Medical Centre PHASE 2
Recruiting
Bedford Park
The Chris O-Brien Lifehouse PHASE 2
Recruiting
Camperdown
Peter MacCallum Cancer Center PHASE 2
Recruiting
Melbourne
Belgium
UZA Research Unit Oncology- route 55 PHASE 2
Recruiting
Edegem
UZ Leuven - Campus Gasthuisberg PHASE 2
Recruiting
Leuven
Canada
William Osler Health System PHASE 2
Recruiting
Brampton
Cross Cancer Institute PHASE 2
Recruiting
Edmonton
The Ottawa Hospital PHASE 2
Recruiting
Ottawa
Princess Margaret Cancer Center at University Health Network PHASE 2
Recruiting
Toronto
BC Cancer PHASE 2
Recruiting
Vancouver
China
The Second XIANGYA Hospital Of Central South University/Oncology Department PHASE 2
Recruiting
Changsha
The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine PHASE 2
Recruiting
Changsha
Cancer Hospital Chinese Academy of Medical Sciences/Cancer Institute PHASE 2
Recruiting
Chaoyang
Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center PHASE 2
Recruiting
Daping
The First Affiliated Hospital of Xiamen University/Medical oncology Department PHASE 2
Recruiting
Fujian
Fujian Provincial Cancer Hospital/Thoracic oncology Department PHASE 2
Recruiting
Fuzhou
Guangdong Provincial People's Hospital PHASE 2
Recruiting
Guangzhou
Beijing Cancer Hospital/Oncology Department PHASE 2
Recruiting
Haidian
Sir Run Run Shaw Hospital Zhejiang University School of Medicine/Oncology Department PHASE 2
Recruiting
Hangzhou
Zhejiang Cancer Hospital/Thoracic Oncology Department PHASE 2
Recruiting
Hangzhou
Anhui Provincial Hospital/Oncology Department PHASE 2
Recruiting
Hefei
The Affiliated Tumor Hospital of Harbin Medical University/Medical Oncology Department PHASE 2
Recruiting
Heilongjiang
Jilin Cancer Hospital/Medical Oncology Department PHASE 2
Recruiting
Jilin
The First Hospital of Jilin University/Oncology Center Department PHASE 2
Recruiting
Jilin
Nanjing Drum Tower Hospital PHASE 2
Recruiting
Nanjing
Jinan Central Hospital/Medical Oncology Department PHASE 2
Recruiting
Shandong
Weifang People's Hospital/Medical Oncology Department PHASE 2
Recruiting
Shandong
Shanghai Chest Hospital/Chest Cancer Institute PHASE 2
Recruiting
Shanghai
Shanghai Chest Hospital/Oncology Department PHASE 2
Recruiting
Shanghai
Shanxi Bethune Hospital PHASE 2
Recruiting
Shanxi
Tangdu Hospital PHASE 2
Recruiting
Shanxi
The first Hospital Affiliated to AMU (Southwest Hospital)/Pneumology Department PHASE 2
Recruiting
Shapingba
Liaoning Cancer hospital PHASE 2
Recruiting
Shenyang
Sichuan Cancer Hospital/Medical Oncology Department PHASE 2
Recruiting
Sichuan
West China Hospital Sichuan University/Lung cancer center PHASE 2
Recruiting
Wenjiang
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department PHASE 2
Recruiting
Wuhan
XuZhou Central Hospital/Oncology Department PHASE 2
Recruiting
Xuzhou
Hunan Cancer Hospital/Medical Oncology Department PHASE 2
Recruiting
Yuelu
The First Affiliated Hospital of Gannan Medical University PHASE 2
Recruiting
Zhanggong
The First Affiliated Hospital Zhejiang University School of Medicine/Respiratory medicine Department PHASE 2
Recruiting
Zhejiang
Henan Cancer Hospital/The 1st pneumology department PHASE 2
Recruiting
Zhengzhou
Denmark
Rigshospitalet, University Hospital of Copenhagen PHASE 2
Recruiting
Copenhagen
France
Centre Hospitalier Regional Vuniversitaire Brest PHASE 2
Recruiting
Brest
Centre Georges-Francois PHASE 2
Recruiting
Dijon
Centre Hospitalier Universitarie Arie Grenoble Alpes (CHUGA) PHASE 2
Recruiting
Grenoble
Hospital de la Timone PHASE 2
Recruiting
Marseille
Centre Antoine Lacassagne Phase 2
Recruiting
Nice
CHU Poitiers PHASE 2
Recruiting
Poitiers
Hopital D'Instruction Des Armees Begin PHASE 2
Recruiting
Saint-mandé
Institut Gustave Roussy PHASE 2
Recruiting
Villejuif
Germany
Evangelische Lungenklinik Berlin PHASE 2
Recruiting
Berlin
Centrum für Integrierte Onkologie - Universitaetsklinikum Koeln PHASE 2
Recruiting
Cologne
University Clinic Carl Gustav Carus PHASE 2
Recruiting
Dresden
University Hospital Heidelberg PHASE 2
Recruiting
Heidelberg
Hong Kong Special Administrative Region
Queen Mary Hospital PHASE 2
Recruiting
Hong Kong
Hong Kong United Oncology Centre PHASE 2
Recruiting
Kowloon
Prince of Wales Hospital PHASE 2
Recruiting
Sha Tin
Hungary
Országos Korányi TBC és Pulmonológiai Intézet Budapest PHASE 2
Recruiting
Budapest
Semmelweis Egyetem PHASE 2
Recruiting
Budapest
Italy
Centro Di Riferimento PHASE 2
Recruiting
Aviano
Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico PHASE 2
Recruiting
Milan
Fondazione IRCCS Istituto Nazionale Dei Tumori PHASE 2
Recruiting
Milan
Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cerevello PHASE 2
Recruiting
Palermo
Arcispedale S. Maria Nuova PHASE 2
Recruiting
Reggio Emilia
IRCCS Istituto Regina Elena Oncologia Medica 1 PHASE 2
Recruiting
Roma
Azienda Ospedaliera Santa Maria di Terni - PHASE 2
Recruiting
Terni
Japan
National Cancer Center Hospital, Tokyo PHASE 2
Recruiting
Chuo-ku
National Cancer Center Hospital East PHASE 2
Recruiting
Kashiwa
Nagoya University Hospital PHASE 2
Recruiting
Nagoya-shi
Osaka City General Hospital PHASE 2
Recruiting
Osaka-shi
Osaka International Cancer Institute PHASE 2
Recruiting
Osaka-shi
Hokkaido University Hospital PHASE 2
Recruiting
Sapporo-shi
Ehime University PHASE 2
Recruiting
Toon-shi
Kanagawa Cancer Center, Yokohama PHASE 2
Recruiting
Yokohama-shi
Tottori University Hospital PHASE 2
Recruiting
Yonago-shi
Netherlands
Netherlands Cancer Institute PHASE 2
Recruiting
Amsterdam
Universiair Medisch Centrum Groningen PHASE 2
Recruiting
Groningen
Poland
Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii PHASE 2
Recruiting
Gdańsk
Katedra i Klinika Pneumonologii, Onkologii i Alergologii Uniwersytetu Medycznego w Lublinie PHASE 2
Recruiting
Lublin
Med Polonia, ul. Obornicka PHASE 2
Recruiting
Poznan
Centrum Medyczne Dom Lekarski PHASE 2
Recruiting
Szczecin
Maria Sklodowska-Curie Cancer Centre and Institute PHASE 2
Recruiting
Warszawa
Republic of Korea
Chungbuk National University Hospital PHASE 2
Recruiting
Cheongju-si
Chonnam National University Hwasun Hospital PHASE 2
Recruiting
Hwasun
Asan Medical Center PHASE 2
Recruiting
Seoul
Konkuk University Medical Center PHASE 2
Recruiting
Seoul
Samsung Medical Center PHASE 1
Recruiting
Seoul
Samsung Medical Center PHASE 2
Recruiting
Seoul
Seoul National University Hospital PHASE 1 (recruiting) and PHASE 2 (not yet recruiting)
Recruiting
Seoul
Seoul National University Hospital PHASE 2
Recruiting
Seoul
Seoul Saint Mary's Hospital PHASE 2
Recruiting
Seoul
Yonsei Cancer Center, Severance Hospital PHASE 1 (recruiting) & PHASE 2 (recruiting)
Recruiting
Seoul
Singapore
National Cancer Center Singapore PHASE 2
Recruiting
Singapore
National University Hospital PHASE 2
Recruiting
Singapore
Spain
Hospital Universitario Dexeus - Grupo Quironsalud PHASE 2
Recruiting
Barcelona
Vall d'Hebron University Hospital PHASE 2
Recruiting
Barcelona
Fundacion MD Anderson PHASE 2
Recruiting
Madrid
Hospital HM Sanchinarro PHASE 2
Recruiting
Madrid
Hospital Universitario 12 de Octubre PHASE 2
Recruiting
Madrid
START Madrid-FJD PHASE 2
Recruiting
Madrid
Clinica Universidad de Navarra PHASE 2
Recruiting
Pamplona
Instituto Valenciano de Oncología PHASE 2
Recruiting
Valencia
Taiwan
National Cheng Kung University Hospital PHASE 2
Recruiting
Tainan
Mackay Memorial Hospital PHASE 2
Recruiting
Taipei
National Taiwan University Hospital PHASE 2
Recruiting
Taipei
United Kingdom
Imperial College London - Hammersmith Hospital PHASE 2
Recruiting
London
Sarah Cannon Research Institute PHASE 2
Recruiting
London
The Royal Marsden NHS Foundation Trust PHASE 2
Recruiting
London
The Christie NHS Foundation Trust PHASE 2
Recruiting
Manchester
Contact Information
Primary
Turning Point Therapeutics Medical Information
medinfo@tptherapeutics.com
+1 (855) 427-5878
Backup
Zai Lab (Shanghai) Co., Ltd, MD
Time Frame
Start Date: February 27, 2017
Estimated Completion Date: December 2024
Participants
Target number of participants: 500
Treatments
Experimental: Repotrectinib (TPX-0005)
Phase 1~Oral repotrectinib (TPX-0005):~Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.~Phase 2~Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts~EXP-1: ROS1 TKI-naïve ROS1+ NSCLC~EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC~EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)~EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)~EXP-5: TRK TKI-naïve NTRK+ solid tumors~EXP-6: TRK TKI-pretreated NTRK+ solid tumors
Authors
NIshan Tchekmedyain, Benjamin Phillip, Arkadiusz Dudek, Christian Rolfo, Faisal Adhami, John Nemunaitis, Viola Zhu, Mark Awad, Benjamin Levy, Samuel Ejadi, Misako Nagasaka, Robert Ramirez, Luis Raez, Mihran Shirinian, Saleha Sajid, Samer Kasbari, Christina Baik, Nashat Gabrail, Yasir Elamin, Lyudmila Bazhenova, Shirish Gadgeel, Christine Bestvina, Karen Reckamp, Alice Shaw, Andrew Pippas, Robert Doebele, Dwight Owen, Vamsidhar Velcheti, Matthias Weiss, Peter Anderson, Stephen Liu, Jessica Bauman, Philip E Lammers, Haeseong Park, Benjamin Creelan, Marianna Koczywas, Alexander Drilon, Brian Van Tine, Petros Nikolinakos, Dipesh Uprety, Katherine Scilla, Greg Gerstner, Xiang Wu, Yang Yu, Nicolas Isambert, Alice Hervieu, Benjamin Besse, Denis Moro-Sibilot, Elisa Fontana, Anna Patrikidou, Christian Grohe, Carole Helissey, Laurent Greillier, Martin Wermke, Gilles Robinet, Esma Saada-Bouzid, Jurgen Wolf, Alex Spria, James Yang, Pawel Krawczyk, Ardman Shergill, Christian Springfield, Yiping Zhang, Marina Garassino, Kye-Young Lee, Yong He, Junping Zhang, Xiufeng Hu, Yping Zhang, Chunhong Hu, Liyan Jiang, Meili Sun, Liang Gong, Alexander Drillon, Yasushi Goto, Kristoffer Rohrberg, Xiang Wang, Jung Yong Hong, Haichuan Su, Gen Lin, Guohua Yu, Leonid Shunkayov, Rodryg Ramlau, Naozumi Hashimoto, Jie Meng, Angel Guerrero, Ben Solomon, Shun Lu, Fernandez de Sanmamed, Claudia Maria Bareggi, Andres Aguilar, Wenxiu Yao, Dong-Wan Kim, Jacky Li, Muhammad Beg, Nishan Tchekmedyian, Tsang-En Wang, Jingxun Wu, Christophe Dooms, Liyun Miao, Herbert Loong, David Pinato, Enrique Grande, Scott Moerdler, Piotr Serwatowski, Haesong Park, Vamsidhar Velchetti, Ian Anderson, Jessica Lin, Ki Hyeong Lee, Koichi Goto, Steven Kao, Junling Li, Terufumi Kato, Victor Moreno, Luis Paz-Ares, Nong Yang, Hans Prenen, Jiuwei Cui, Dariusz Kowalski, Feng Luo, Young-Chul Kim, Paul Wheatley-Price, James Ho, Yueyin Pan, Byoung Chul Cho, Rui Ma, Syed Kazmi, Chia-Jui Yen, Matthew Krebs, Huaqiu Shi, Francesco Grossi, Emiliano Calvo, Sophie Sun, Satoshi Oizumi, Sanjay Popat, Quincy Chu, Sang-We Kim, Kejing Ying, Geoffrey Liu, Jeeyun Lee, Thomas Yau, Masahiro Kodani, Jin-Hyoung Kang, Roberto Ferrara, Irene Moreno, Alessandra Bearz, Valentina Boni, Ross Soo, Jinji Yang, Motohiro Tamiya, Jian Fang, Sergio Bracarda, Darren Lim, Maria Pagano, Ross Camidge, Masahiro Morise, Ignacio Gil-Bazo, Christos Karapetis, Haruko Daga, Joop de Langen, Xiaorong Dong, Enriqueta Felip, Parneet Cheema, Naoyuki Nogami, Jun Sakakibara, Jianying Zhou, Julio Peguero, Francesco Verderame, Ying Cheng, Anthonie Van der Wekken, Federico Cappuzzo, Rafal Dziadziuszko, Veronika Muller
Sponsors
Collaborators: Zai Lab (Shanghai) Co., Ltd.
Leads: Turning Point Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials